Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNYSE:EBSNASDAQ:INVANYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$21.98-0.6%$20.37$14.40▼$47.00$1.46B1.13955,997 shs978,039 shsEBSEmergent Biosolutions$6.99-1.7%$6.21$4.02▼$15.10$379.40M2.091.73 million shs917,382 shsINVAInnoviva$19.20-1.0%$19.75$16.21▼$22.00$1.21B0.37696,031 shs617,656 shsJNJJohnson & Johnson$155.90+0.2%$153.68$140.68▼$169.99$375.37B0.418.05 million shs3.48 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics0.00%+8.30%+11.72%+39.26%-38.81%EBSEmergent Biosolutions0.00%+10.17%+10.08%+54.30%-7.29%INVAInnoviva0.00%-3.81%-8.05%+8.35%+17.58%JNJJohnson & Johnson0.00%+2.27%+1.64%+1.88%+7.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics2.4486 of 5 stars4.43.00.00.01.10.00.0EBSEmergent Biosolutions4.0087 of 5 stars3.51.00.04.60.02.51.3INVAInnoviva3.9228 of 5 stars3.50.00.04.20.61.71.9JNJJohnson & Johnson4.8486 of 5 stars2.35.04.23.93.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.89Moderate Buy$50.11128.04% UpsideEBSEmergent Biosolutions 3.00Buy$14.33105.05% UpsideINVAInnoviva 3.00Buy$55.00186.46% UpsideJNJJohnson & Johnson 2.55Moderate Buy$170.889.61% UpsideCurrent Analyst Ratings BreakdownLatest EBS, JNJ, CLDX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/5/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.005/13/2025JNJJohnson & JohnsonLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025JNJJohnson & JohnsonLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$169.00 ➝ $153.005/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/28/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.004/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M207.79N/AN/A$11.26 per share1.95EBSEmergent Biosolutions$1.04B0.36$1.92 per share3.64$8.91 per share0.78INVAInnoviva$358.71M3.36$3.42 per share5.61$11.03 per share1.74JNJJohnson & Johnson$88.82B4.22$13.11 per share11.89$29.69 per share5.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)EBSEmergent Biosolutions-$190.60M-$2.71N/A3.38N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A12.39N/A-16.15%15.77%8.41%7/29/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9917.3414.082.3624.42%33.46%13.30%7/16/2025 (Estimated)Latest EBS, JNJ, CLDX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025INVAInnoviva$0.43N/AN/AN/A$87.10 millionN/A7/16/2025Q2 2025JNJJohnson & Johnson$2.65N/AN/AN/A$22.85 billionN/A5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/7/2025Q1 2025EBSEmergent Biosolutions$0.49$0.71+$0.22$1.19$218.50 million$222.20 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.203.34%N/A57.84%64 YearsLatest EBS, JNJ, CLDX, and INVA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A21.6721.67EBSEmergent Biosolutions1.206.323.51INVAInnoviva0.402.482.30JNJJohnson & Johnson0.491.261.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AEBSEmergent Biosolutions78.40%INVAInnoviva99.12%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%EBSEmergent Biosolutions1.20%INVAInnoviva2.25%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.46 millionOptionableEBSEmergent Biosolutions2,42054.28 million53.63 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableEBS, JNJ, CLDX, and INVA HeadlinesRecent News About These CompaniesTandem Investment Advisors Inc. Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comMeritage Portfolio Management Sells 1,844 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comZWJ Investment Counsel Inc. Buys 2,851 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comResonant Capital Advisors LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comRobert Wood Johnson Foundation Trims Stock Position in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comTeacher Retirement System of Texas Lowers Position in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comFirst Horizon Advisors Inc. Raises Stock Position in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comRevisor Wealth Management LLC Has $892,000 Stake in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comHudson Edge Investment Partners Inc. Has $6.66 Million Stock Position in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarJuly 4 at 9:56 AM | zacks.com2 Bulletproof Dividend Stocks to Buy in JulyJuly 4 at 9:40 AM | 247wallst.comGoldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy TailwindsJuly 4 at 6:48 AM | msn.comPinnacle Financial Partners Inc Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comMiller Howard Investments Inc. NY Acquires 99,040 Shares of Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comKanawha Capital Management LLC Has $24.87 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comMoody Lynn & Lieberson LLC Has $22.09 Million Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comFirst Bank & Trust Buys 3,952 Shares of Johnson & Johnson (NYSE:JNJ)July 4 at 5:04 AM | marketbeat.comHarbour Trust & Investment Management Co Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:04 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Keybank National Association OHJuly 4 at 4:54 AM | marketbeat.comYukon Wealth Management Inc. Invests $741,000 in Johnson & Johnson (NYSE:JNJ)July 4 at 4:54 AM | marketbeat.comSumitomo Mitsui DS Asset Management Company Ltd Has $88.90 Million Stake in Johnson & Johnson (NYSE:JNJ)July 4 at 4:45 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEBS, JNJ, CLDX, and INVA Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$21.98 -0.14 (-0.61%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$21.28 -0.70 (-3.16%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Emergent Biosolutions NYSE:EBS$6.99 -0.12 (-1.69%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$6.98 0.00 (-0.07%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Innoviva NASDAQ:INVA$19.20 -0.20 (-1.03%) Closing price 07/3/2025 01:23 PM EasternExtended Trading$19.20 0.00 (0.00%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Johnson & Johnson NYSE:JNJ$155.90 +0.34 (+0.22%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$155.75 -0.15 (-0.10%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
